Association between periodontal disease and osteoporosis in postmenopausal women: a protocol for systematic review and meta-analysis

Qi, Jing; Liu, E; Guo, Yufeng; Hu, Jie-Mei; Liu, Yuting; Chen, Guang; Yue, Haiquan

doi:10.1136/bmjopen-2021-049277

Cited by 5 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42021225746. The protocol for systematic review and meta-analysis was published on the BMJ Open [ 8 ].…”

Section: Methodsmentioning

confidence: 99%

Association between periodontal disease and osteoporosis in postmenopausal women: A systematic review and meta-analysis

Qi,

Chen,

Pang

et al. 2023

Heliyon

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Association between periodontal disease and osteoporosis in postmenopausal women: A systematic review and meta-analysis

Qi,

Chen,

Pang

et al. 2023

Heliyon

Self Cite

View full text Add to dashboard Cite

“…Periodontitis is the irreversible destructive stage of a persistent bacterial infection, while gingivitis is the reversible inflammatory stage. [13][14][15][16][17] Untreated periodontitis causes soft tissue and bone degeneration, tooth movement, and eventual tooth loss.…”

Section: Graphical Abstractmentioning

confidence: 99%

Identification of Repurposed FDA Drugs by Targeting Sclerostin via the Wnt Pathway for Alveolar Bone Formation

Yadalam,

Anegundi,

Ramadoss

et al. 2024

European Journal of General Dentistry

View full text Add to dashboard Cite

Objective Natural wingless-related integration site (Wnt) pathway antagonist sclerostin (SOST) has attracted much attention because unusual bone illnesses characterized by the increased bone mass result from its absence of action. The Wnt ligand is prevented from attaching to the Frizzled family receptor when SOST is present. In the active destruction complex, -catenin is phosphorylated. -Catenin molecules do not enter the nucleus and are broken down by a proteasome. As a result, Wnt-responsive genes are not activated, which lowers bone formation and raises bone resorption. A humanized monoclonal antibody called romosozumab binds to and inhibits SOST with significant cardiac side effects. As a result, the current study's objective is to find and screen Food and Drug Administration (FDA) medications that target SOST. Materials and Methods SOST's structure was retrieved from Protein Data Bank (PDB) (ID: 6l6r). Pharmacophore modeling and molecular operating environment-based virtual testing of FDA-approved medicines. Using the Desmond program, docking and molecular dynamics simulations were performed. Results Our findings revealed medications with FDA approval (ZINC000253387843) Amphotericin B. The stability and receptor–ligand interactions are pretty substantial, as demonstrated by the findings of docking and Molecular dynamics simulations, which have a docking score of −7.3 k/mol and root mean square deviation stability at 40 nanoseconds, respectively. Conclusion The suggested pharmacological therapy shows promise since it uses the Wnt pathway to target the primary bone formation mechanism. However, additional prospective studies are required to apply the available data to clinical practice.

show abstract

“…Radiographic bone loss (RBL) should be used in cases if the CAL is unavailable (Tonetti et al, 2017). Loss of alveolar crestal height (ACH), oral hygiene simplified (OHI-S) and sites with bleeding on probing (BOP) percentage are among other important clinical parameters in the evaluation of periodontal status (Qi et al, 2021). Apart from that, identification of cavities and periodontal lesions, maxillary sinusitis and other lesions in the oral and maxillofacial field as well as osteoporosis can be done with the use of computer-aided diagnosis (CAD) (Wang and McCauley.…”

Section: Association Between Postmenopausal Osteoporosis and Periodon...mentioning

confidence: 99%

Overview on postmenopausal osteoporosis and periodontitis: The therapeutic potential of phytoestrogens against alveolar bone loss

et al. 2023

View full text Add to dashboard Cite

Osteoporosis and periodontitis are two major chronic diseases of postmenopausal women. The association between these two diseases are evident through systemic bone loss and alveolar bone loss. Both postmenopausal osteoporosis and periodontitis impose a considerable personal and socioeconomic burden. Biphosphonate and hormone replacement therapy are effective in preventing bone loss in postmenopausal osteoporosis and periodontitis, but they are coupled with severe adverse effects. Phytoestrogens are plant-based estrogen-like compounds, which have been used for the treatment of menopause-related symptoms. In the last decades, numerous preclinical and clinical studies have been carried out to evaluate the therapeutic effects of phytoestrogens including bone health. The aim of this article is to give an overview of the bidirectional interrelationship between postmenopausal osteoporosis and periodontitis, summarize the skeletal effects of phytoestrogens and report the most studied phytoestrogens with promising alveolar bone protective effect in postmenopausal osteoporosis model, with and without experimental periodontitis. To date, there are limited studies on the effects of phytoestrogens on alveolar bone in postmenopausal osteoporosis. Phytoestrogens may have exerted their bone protective effect by inhibiting bone resorption and enhancing bone formation. With the reported findings on the protective effects of phytoestrogens on bone, well-designed trials are needed to better investigate their therapeutic effects. The compilation of outcomes presented in this review may provide an overview of the recent research findings in this field and direct further in vivo and clinical studies in the future.

show abstract

Association between periodontal disease and osteoporosis in postmenopausal women: a protocol for systematic review and meta-analysis

Cited by 5 publications

References 29 publications

Association between periodontal disease and osteoporosis in postmenopausal women: A systematic review and meta-analysis

Association between periodontal disease and osteoporosis in postmenopausal women: A systematic review and meta-analysis

Identification of Repurposed FDA Drugs by Targeting Sclerostin via the Wnt Pathway for Alveolar Bone Formation

Overview on postmenopausal osteoporosis and periodontitis: The therapeutic potential of phytoestrogens against alveolar bone loss

Contact Info

Product

Resources

About